Doximity, Inc. – Consensus ‘buy’ rating and 12.6% Upside Potential

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

Doximity, Inc. with ticker code (DOCS) have now 16 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between $75.00 and $30.00 suggesting an average Analsyt target price of $55.63. Given that the stocks previous close was at $49.40 and the analysts are correct then there would likely be a percentage uptick in value of 12.6%. Also worth taking note is the 50 day moving average now sits at $43.71 and the 200 day moving average is $32.25. The market cap for the company is 9.22B. The stock price is currently at: $52.21 USD

The potential market cap would be $10,384,740,806 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 60.01, revenue per share of $2.78 and a 11.83% return on assets.

Doximity, Inc. provides a digital platform for United States (U.S) medical professionals. The Company’s cloud-based platform provides tools to its members, which help them to collaborate with colleagues, coordinate patient care, conduct virtual patient visits, stay up-to-date with medical news and research, and manage careers. The Company supports physicians in practice of medicine with mobile and clinical workflow tools, such as voice and video telehealth, secure messaging and digital faxing. The Company’s platform offers marketing, hiring, and telehealth solutions. Its marketing solutions enable pharmaceutical and health system customers to get content, services, and peer connections to medical professionals through a variety of modules. Its hiring solutions provide digital recruiting capabilities to health systems and medical recruiting firms. Its telehealth solutions consist of software tools that include voice and video dialers, designed to connect patients with care providers.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    Dr. Martens (LON:DOCS) reports first half results aligning with expectations, highlighting strategic progress in marketing, cost reduction, and U.S. growth.

      Search

      Search